BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015; 7(13): 1742-1754 [PMID: 26167247 DOI: 10.4254/wjh.v7.i13.1742]
URL: https://www.wjgnet.com/1007-9327/full/v7/i13/1742.htm
Number Citing Articles
1
Machiko Umemura, Koji Ogawa, Kenichi Morikawa, Akinori Kubo, Yoshimasa Tokuchi, Ren Yamada, Takashi Kitagataya, Taku Shigesawa, Tomoe Shimazaki, Megumi Kimura, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Masato Nakai, Takuya Sho, Goki Suda, Mitsuteru Natsuizaka, Kota Ono, Kazumoto Murata, Masaya Sugiyama, Masashi Mizokami, Naoya Sakamoto. Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patientsHepatology Research 2022;  doi: 10.1111/hepr.13768
2
Ryosuke Muroyama, Ryo Nakagawa, Yasuo Matsubara, Yoshihiro Hirata, Masao Omata, Hiroshi Shirasawa, Naoya Kato. Fusion HBx from HBV integrant affects hepatocarcinogenesis through deregulation of ER stress responseVirus Research 2022; 315: 198787 doi: 10.1016/j.virusres.2022.198787
3
Yong-an Ye, Xiao-ke Li, Da-qiao Zhou, Xiao-ling Chi, Qin Li, Li Wang, Bing-jiu Lu, De-wen Mao, Qi-kai Wu, Xian-bo Wang, Ming-xiang Zhang, Jing-dong Xue, Yong Li, Wei Lu, Jian-chun Guo, Feng Jiang, Xin-wei Zhang, Hong-bo Du, Xian-zhao Yang, Hui Guo, Da-nan Gan, Zhi-guo Li. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled TrialChinese Journal of Integrative Medicine 2018; 24(9): 653 doi: 10.1007/s11655-018-3011-5
4
Giordano Madeddu, Silvia Ortu, Giovanni Garrucciu, Ivana Maida, Michela Melis, Alberto Augusto Muredda, Maria Stella Mura, Sergio Babudieri. DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapyJournal of Medical Virology 2017; 89(7): 1208 doi: 10.1002/jmv.24742
5
Fumihiko Takeuchi, Sotaro Ikeda, Yuta Tsukamoto, Yoshikazu Iwasawa, Chen Qihao, Yukie Otakaki, Ouda Ryota, Wan-Ling Yao, Ryo Narita, Hijikata Makoto, Koichi Watashi, Takaji Wakita, Koh Takeuchi, Kazuaki Chayama, Amane Kogure, Hiroki Kato, Takashi Fujita, Wang-Shick Ryu. Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitorPLOS ONE 2019; 14(2): e0212233 doi: 10.1371/journal.pone.0212233
6
Shin Hwang, Gi-Won Song, Dong-Hwan Jung, Young-In Yoon, Hyun Ju Yoo, Eunyoung Tak. High-dose tenofovir is not effective in suppressing hepatitis B virus replication in patients with hepatocellular carcinoma progression: a preliminary resultKorean Journal of Hepato-Biliary-Pancreatic Surgery 2016; 20(1): 8 doi: 10.14701/kjhbps.2016.20.1.8
7
Yanhua Ding, Jinfeng Lou, Hong Chen, Xiaojiao Li, Min Wu, Cuiyun Li, Jingrui Liu, Chengjiao Liu, Qingmei Li, Hong Zhang, Junqi Niu. Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infectionBritish Journal of Clinical Pharmacology 2017; 83(5): 1056 doi: 10.1111/bcp.13184
8
Tony S. Brar, Eric Hilgenfeldt, Consuelo Soldevila-Pico. Precision Molecular Pathology of Liver CancerMolecular Pathology Library 2018; : 1 doi: 10.1007/978-3-319-68082-8_1
9
Jingying Qiu, Bixue Xu, Qineng Gong, Weidong Pan, Changxiao Liu, Zhengming Huang, Xiaoke Gu, Guangyi Liang. Synthesis and Biological Evaluation of Matijin-Su Derivatives as Potential Antihepatitis B Virus and Anticancer AgentsChemistry & Biodiversity 2016; 13(11): 1584 doi: 10.1002/cbdv.201600113
10
Reham Mohamed El shabrawy. The Role of Oncogenic Infectious Agents in Causing Liver, Stomach, Urinary Bladder, Head and Neck and Cervical CancersJournal of Human Virology & Retrovirology 2016; 3(2) doi: 10.15406/jhvrv.2016.03.00087
11
Kazuhiko Koike, Kazuaki Suyama, Hiroshi Ito, Hiroshi Itoh, Wataru Sugiura. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patientsHepatology Research 2018; 48(1): 59 doi: 10.1111/hepr.12902
12
Elena Raffetti, Giovanna Fattovich, Francesco Donato. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysisLiver International 2016; 36(9): 1239 doi: 10.1111/liv.13142
13
Zhi-Qin Li, Chun-Ling Hu, Ping Yu, Xin-Yu Gu, Jia-Jia Zhang, Hua Li, Hong-Yu Zhang, Jun Lv, Yan-Min Liu, Qing-Lei Zeng, Jing-Ya Yan, Zu-Jiang Yu, Yi Zhang. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factorsClinics and Research in Hepatology and Gastroenterology 2017; 41(3): 311 doi: 10.1016/j.clinre.2016.11.007
14
Rifat Munir. Combination Therapy Against Multidrug Resistance2020; : 183 doi: 10.1016/B978-0-12-820576-1.00010-2
15
Francesco Paolo Russo, Alberto Zanetto, Elisa Pinto, Sara Battistella, Barbara Penzo, Patrizia Burra, Fabio Farinati. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?International Journal of Molecular Sciences 2022; 23(1): 500 doi: 10.3390/ijms23010500
16
B Wang, K Agarwal, D Joshi. Management of chronic hepatitis B before and after liver transplantationFrontline Gastroenterology 2018; 9(1): 79 doi: 10.1136/flgastro-2016-100768